Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.33 |
| ▸ | CTSB | P07858 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TOP2A | P11388 | 1/20 | 0.31 |
| ▸ | CTSG | P08311 | 2/20 | 0.31 |
| ▸ | KLK7 | P49862 | 2/20 | 0.31 |
| ▸ | KLK14 | Q9P0G3 | 2/20 | 0.31 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.31 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.30 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.30 |
| ▸ | CTRC | Q99895 | 1/20 | 0.30 |
| ▸ | LOX | P28300 | 1/20 | 0.30 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6045098 | 0.75 | PTGS1 (0.32) | BRD4CREBBPHSD11B1LMNACTSG | |
| SCHEMBL28333843 | 0.72 | CTSB (0.42) | CTSBHSD11B1LMNAKDM4EPTGS2 | |
| SCHEMBL23914271 | 0.70 | CYP19A1 (0.51) | CYP19A1CTRC | |
| SCHEMBL30674005 | 0.70 | CYP19A1 (0.51) | CYP19A1CTRC | |
| SCHEMBL23162797 | 0.68 | HSD11B1 (0.48) | HSD11B1LMNAPTGS2 | |
| SCHEMBL14472622 | 0.65 | LMNA (0.37) | BRD4CREBBPHSD11B1LMNAPTGS2 | |
| SCHEMBL10180103 | 0.65 | PTGS2 (0.55) | HSD11B1LMNAPTGS2ALDH1A1 | |
| SCHEMBL8770429 | 0.64 | LOX (0.37) | HSD11B1LMNALOX | |
| SCHEMBL10192344 | 0.64 | PTGS2 (0.58) | HSD11B1LMNAKDM4EPTGS2ALDH1A1 | |
| SCHEMBL10856385 | 0.64 | SMN1; SMN2 (0.52) | BRD4CREBBPLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060135506-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a calcium modulating agent for the treatment of pain, inflammation or inflammation mediated disorders | PHARMACIA CORPORATION | 2006-06-22 | — | — | US | disclosed |
| US-20050159419-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a central nervous system stimulant for the treatment of central nervous system damage | PHARMACIA CORPORATION (US) | 2005-07-21 | — | — | US | disclosed |
| US-20050159403-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a calcium modulating agent for the treatment of central nervous system damage | PHARMACIA CORPORATION | 2005-07-21 | — | — | US | disclosed |
| US-20050130971-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and phosphodiesterase inhibitor for the treatment of ischemic mediated central nervous system disorders or injury | PHARMACIA CORPORATION | 2005-06-16 | — | — | US | disclosed |
| US-20050107387-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a peroxisome proliferator activated receptor agonist for the treatment of ischemic mediated central nervous system disorders | PHARMACIA CORPORATION (US) | 2005-05-19 | — | — | US | disclosed |
| US-20050101597-A1 | Compositions of a cyclooxygenase-2 selective inhibitior and a non-NMDA glutamate modulator for the treatment of central nervous system damage | PHARMACIA CORPORATION | 2005-05-12 | — | — | US | disclosed |
| US-20050085478-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a low-molecular-weight heparin for the treatment of central nervous system damage | PHARMACIA CORPORATION | 2005-04-21 | — | — | US | disclosed |
| US-20050085479-A1 | Mediated central nervous system compositions of a cyclooxygenase-2 selective inhibitor and a corticotropin releasing factor antagonist for the treatment of ischemic disorders or injury | PHARMACIA CORPORATION | 2005-04-21 | — | — | US | disclosed |
| US-20050075341-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and an IKK inhibitor for the treatment of ischemic mediated central nervous system disorders or injury | PHARMACIA CORPORATION (US) | 2005-04-07 | — | — | US | disclosed |
| US-20050070524-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and an anticonvulsant agent for the treatment of central nervous system disorders | PHARMACIA CORPORATION | 2005-03-31 | — | — | US | disclosed |
| US-20050065154-A1 | Treatment of migraine accompanied by nausea with a combination of cyclooxygenase-2 selective inhibitors and anti-nausea agents | PHARMACIA CORPORATION | 2005-03-24 | — | — | US | disclosed |
| US-20050054646-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and an antioxidant agent for the treatment of central nervous system disorders | PHARMACIA CORPORATION | 2005-03-10 | — | — | US | disclosed |
| US-20050026919-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a cholinergic agent for the treatment of reduced blood flow or trauma to the central nervous system | PHARMACIA CORPORATION | 2005-02-03 | — | — | US | disclosed |
| US-20050009733-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a potassium ion channel modulator for the treatment of central nervous system damage | PHARMACIA CORPORATION | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054646-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and an antioxidant agent for the treatment of central nervous system disorders | TXNRD2, PRDX5, PTGS2 | BRD4 3602/4885CREBBP 2520/4885CYP19A1 2495/4885 |
| US-20050107387-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a peroxisome proliferator activated receptor agonist for the treatment of ischemic mediated central nervous system disorders | PPARA, PPARG, PTGER2 | BRD4 1888/4885CREBBP 1108/4885CYP19A1 1765/4885 |
| US-20050009733-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a potassium ion channel modulator for the treatment of central nervous system damage | KCNJ2, KCNN2, KCNK2 | BRD4 2429/4885CREBBP 2320/4885CYP19A1 3381/4885 |
| US-20050159419-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a central nervous system stimulant for the treatment of central nervous system damage | GAP43, PTGS2, CNR2 | BRD4 2443/4885CREBBP 604/4885CYP19A1 1640/4885 |
| US-20050085479-A1 | Mediated central nervous system compositions of a cyclooxygenase-2 selective inhibitor and a corticotropin releasing factor antagonist for the treatment of ischemic disorders or injury | CRH, CRHR2, CRHR1 | BRD4 4630/4885CREBBP 1352/4885CYP19A1 1694/4885 |
| US-20060135506-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a calcium modulating agent for the treatment of pain, inflammation or inflammation mediated disorders | PTGS2, PTGES2, PTGS1 | BRD4 1438/4885CREBBP 839/4885CYP19A1 2143/4885 |
| US-20050085478-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a low-molecular-weight heparin for the treatment of central nervous system damage | PTGS2, PTGS1, PTGER2 | BRD4 4049/4885CREBBP 3724/4885CYP19A1 4272/4885 |
| US-20050101597-A1 | Compositions of a cyclooxygenase-2 selective inhibitior and a non-NMDA glutamate modulator for the treatment of central nervous system damage | GRIN1, GRIN2A, GRIN2B | BRD4 3606/4885CREBBP 2760/4885CYP19A1 3778/4885 |
| US-20050070524-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and an anticonvulsant agent for the treatment of central nervous system disorders | PTGS2, PTGER2, PTGES2 | BRD4 2606/4885CREBBP 2279/4885CYP19A1 938/4885 |
| US-20050026919-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a cholinergic agent for the treatment of reduced blood flow or trauma to the central nervous system | ACHE, PTGER2, PTGS2 | BRD4 2259/4885CREBBP 2946/4885CYP19A1 2936/4885 |
| US-20050130971-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and phosphodiesterase inhibitor for the treatment of ischemic mediated central nervous system disorders or injury | PDE2A, PDE3B, PDE3A | BRD4 3879/4885CREBBP 2454/4885CYP19A1 1460/4885 |
| US-20050159403-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a calcium modulating agent for the treatment of central nervous system damage | PTGS2, PTGS1, PTGIS | BRD4 3080/4885CREBBP 2091/4885CYP19A1 3331/4885 |
| US-20050065154-A1 | Treatment of migraine accompanied by nausea with a combination of cyclooxygenase-2 selective inhibitors and anti-nausea agents | PTGS2, PTGS1, PTGES2 | BRD4 769/4885CREBBP 1619/4885CYP19A1 1518/4885 |
| US-20050075341-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and an IKK inhibitor for the treatment of ischemic mediated central nervous system disorders or injury | IKBKE, IKBKG, IKBKB | BRD4 2100/4885CREBBP 1578/4885CYP19A1 4043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.